ClinicalTrials.gg
Enrolling by invitationNCT02347540QoHUpdated Jul 28, 2022

Heart Failure and Related Risk-factors After Preeclampsia

An observational study in Heart Failure, Cardiovascular Diseases and Pre-Eclampsia, sponsored by Maastricht University Medical Center. Enrolling by invitation at 1 site in Netherlands. Open to female participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-07-28.

Sponsored by Maastricht University Medical Center · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2024, 1 year 11 months ago, but the record still lists the study as enrolling by invitation.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Cross-sectional
Enrollment
2,580
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 14 studies in Heart Failure by Maastricht University Medical Center — 4 open to participants now, 4 under way, none of them phase 3. Heart Failure · Maastricht University Medical Center.

Started
2014
with 1 other
Observational
6 of 14
3 open now
Registered
6th of 14
by date

Among the 14 studies in Heart Failure by Maastricht University Medical Center, this one is one of 2 that started in 2014, is one of 6 observational ones, and was the 6th registered.

Heart Failure

6,340 studies on the registry are indexed under Heart Failure; 1,397 are open to participants now.

Browse Heart Failure studies →

Open to participants now

4 of the 14 studies in Heart Failure by Maastricht University Medical Center are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Who these studies take

Of the 968 Heart Failure studies recruiting now, 691 (71%) set no upper age limit and 90 (9%) stop at 75 or younger; 64 take children under 18; 97 take healthy volunteers.

This study: 18 Years and older · female · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies in Heart Failure by Maastricht University Medical Center, or all of them as a file.
02

Study summary

This study is a cross-sectional case-control study where classical as well as more innovative risk factors for CVD will be explored.

In western countries, more women than men die of cardiovascular disease (CVD), making CVD in women an important public health issue. Misdiagnosis of CVD in women is frequently observed, posing the clinician for diagnostic and therapeutic dilemmas that can easily result in inadequate treatment and worse prognosis. Despite these challenges, CVD in women has been underexposed in scientific research.

Women have gender-specific risk factors like a history of preeclampsia (PE) that contribute to their risk for CVD. PE complicates 5-10% of pregnancies, recurs in \~25% and is associated with a 2-4 fold increased risk for CVD. Moreover, pre-symptomatic heart failure (HF) stage B occurs in 40% of women with a history of PE. HF stage B is thought to precede the development of the, mortality related, clinical HF stages C and D (structural heart disease in combination with symptomatic disease). Early detection and tailored intervention of women with stage B HF decreases progression to the clinical stages and might therefore improve clinical outcome and cardiovascular related mortality.

Phenotypic presentation of HF is currently split up between systolic HF also called HF with reduced ejection fraction (HFrEF) and diastolic HF or HF with preserved ejection fraction (HFpEF). Women more often have HFpEF in contrast to men. Different pathophysiology and disease progression in women compared to men seems to be an important underlying factor. The current clinical HF diagnostic tools (e.g. natriuretic hormones and high sensitivity troponins) fail to identify early changes that prelude adverse cardiac remodelling and HF, and do not discriminate between HFrEF and HFpEF. Moreover, there are sex-related differences in biomarker levels for detection of CVD. As a result, clinicians are forced to wait for the failing heart to become clinically evident before they can intervene. Therefore, there is an urgent need to assess novel biomarkers that could help select high risk women needing further follow up and intervention. Biomarkers may not only improve early diagnosis but may also unravel disease pathways of HFpEF. Especially when combined with measurements of subclinical, surrogate risk markers.

Objectives

  • To determine the impact of PE on incidence of macro-and micro-vascular dysfunction reflected by surrogate measures for coronary artery disease (CAD) and HFpEF.
  • To perform a genome wide association study (GWAS) and associate novel biomarker expression levels with endothelial function, cardiac diastolic function and IMT measurement.
  • To identify risk factors and surrogate measures for CVD in a) former PE patients without HFpEF, b) former PE patients with HFpEF and c) healthy parous controls.

Study population Cases: women with a history of PE Controls: women with uncomplicated pregnancies in the history. Measurements will be performed in clusters at postpartum intervals of: ½-2, 5-10, 10-15 and 15-30 years. Number of inclusions will be: 425, 350, 282 and 233 for each follow-up group respectively.

Primary endpoints The prevalence of macro- and microvascular dysfunction in former PE patients. Novel biomarker detection in former PE patients associated with HF in general and HFpEF in particular.

Secondary endpoints

  • Lifestyle (questionnaire)
  • Cognitive ability (questionnaire)
  • Depression score (questionnaire)
  • Metabolic syndrome (MetS)
  • Arterial endothelial function (Flow mediated dilation (FMD))
  • Intima Media Thickness (IMT)
  • Glycocalyx thickness (by means of the Glycocheck)
  • Venous function (plethysmograph)
  • Electrocardiogram (ECG)
  • Ergometry
03

Conditions studied

  • Heart Failure
  • Cardiovascular Diseases
  • Pre-Eclampsia

Keywords

  • Heart Failure
  • Diastolic Dysfunction
  • Pre-Eclampsia
  • Endothelial dysfunction
  • Biological Markers
  • MicroRNAs
  • Circulating cells
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
Yes
Sampling method
Probability sample

Study population

Cases: women with a history of PE. Control group: women with uncomplicated pregnancies in the history H1: PP interval ½ -2 years: n = 2x 425 H2: PP interval 5-10 years: n = 2x 350 H3: PP interval 10-15 years: n = 2x 282 H4: PP interval 15-30 years: n = 2x 233

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Cases

  • Women aged ≥ 18 years
  • ½ till 30 years after the complicated pregnancy
  • Experienced PE in any pregnancy. PE defined as hypertension (systolic BP ≥ 140 mmHg and/or diastolic BP ≥ 90 mmHg) developed after 20 weeks of pregnancy with the development of proteinuria (≥ 300 mg/ 24 hours).
  • Women who had their last delivery at least 6 months ago.

Controls

  • Women aged ≥ 18 years
  • ½ till 30 years after the pregnancy that matches the sequence number of pregnancy of the specifically matched case.
  • Experienced pregnancies that were not complicated by foetal or maternal placental syndrome (pregnancy induced hypertension, preeclampsia, HELLP-syndrome).
  • Women who had their last pregnancy at least 6 months ago.
  • Women with a negative family history for PE (mother and sisters did not experience PE).

Exclusion criteria

Exclusion Criteria:

A potential subject who meets any of the following criteria will be excluded from participation in this study:

Cases

  • Women with auto-immune diseases prior to the complicated pregnancy.
  • Chronic hypertension prior to the complicated pregnancy.
  • Renal disease prior to the complicated pregnancy.
  • Pregnant women
  • Women who do not want to be informed about the results of the tests, or women who do not want their general practitioner and specialist(s) to be informed about the test results.

Control group:

  • Women with auto-immune diseases
  • Chronic hypertension prior to the matched pregnancy.
  • Women with IUGR in the matching pregnancy (p\<10)
  • Solutio placentae in the matching pregnancy
  • Pregnant women
  • Women who do not want to be informed about the results of the tests, or women who do not want their general practitioner and specialist(s) to be informed about the test results.
05

Study design

Observational model
Case-control
Time perspective
Cross-sectional
Enrollment
2,580 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • Women with a history of preeclampsia (cases)

    Cases: women with a history of preeclampsia. Measurements will be performed in a postpartum interval from 0.5 years until 30 years after the first complicated pregnancy. This group will further be subdivided in a subgroup with Heart Failure and a group without Heart Failure.

  • Women with a history of uncomplicated pregnancy (controls)

    Controls include women with a history of uncomplicated pregnancies. The controlgroup will further be subdivided in a subgroup with Heart Failure and a group without Heart Failure.

06

What researchers measure

Primary outcomes

  1. The prevalence of Heart Failure (number with percentage)

    Heart Failure will be assessed with the transthoracic echocardiography based on the criteria of the American Heart Association. The sub classification for Heart Failure with preserved ejection fraction (EF) will be made (EF \>55%)

    Time frame: At time of assessment

Secondary outcomes

  1. Structural en Functional Cardiac Measurements

    The objective is to estimate structural and functional cardiac measurements with the TTE based on the ASA guidelines.

    Time frame: At time of assessment

  2. Metabolic syndrome

    The objective is to assess the prevalence of constituents of the Metabolic syndrome based on the WHO criteria. The prevalence will be reported in number with percentage.

    Time frame: At time of assessment

  3. Arterial endothelial function (Flow mediated dilation (FMD))

    The objective is to estimate NO mediated endothelial function of the brachial artery with ultrasound by FMD and sublingual NTG administration. FMD will be reported in relative increase in diameter (%).

    Time frame: At time of assessment

  4. Common Carotid Intima media thickness

    The objective is to estimate IMT of the common carotid artery in cm using ultrasound.

    Time frame: At time of assessment

  5. Glycocalyx thickness en microvascular tortuosity

    The objective is to estimate the glycocalyx dimensions using sublingual orthogonal polarization spectral (OPS) measurements. Derivative of the glycocalyx (perfused boundary region) will be reported in um. Tortuosity will be reported based on a score system.

    Time frame: At time of assessment

  6. Cognitive, Lifestyle and Depression rates

    To evaluate subjective cognitive functioning and depression rates and lifestyle behavior in formerly preeclamptic women with heart failure compared to controls.

    Time frame: At time of assessment

07

Study locations

1 site
08

References and documents

Publications

  • Janssen EBNJ, Hooijschuur MCE, Lopes van Balen VA, Morina-Shijaku E, Spaan JJ, Mulder EG, Hoeks AP, Reesink KD, van Kuijk SMJ, Van't Hof A, van Bussel BCT, Spaanderman MEA, Ghossein-Doha C. No accelerated arterial aging in relatively young women after preeclampsia as compared to normotensive pregnancy. Front Cardiovasc Med. 2022 Jul 28;9:911603. doi: 10.3389/fcvm.2022.911603. eCollection 2022. PubMed 35966519 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Dec 2014 (actual). Primary completion is estimated for Dec 2024, 120 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 30, 2014
First posted
Jan 27, 2015
StartActual
Dec 2014
Primary completionEst.
Dec 2024
CompletionEst.
Jul 2025
Last update
Jul 28, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 28, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02347540
Responsible party
Sponsor
First posted
Jan 27, 2015
Start date
Dec 2014
Primary completion
Dec 2024 (estimated)
Completion
Jul 2025 (estimated)
Last update
Jul 28, 2022

Study contacts

Marc EA Spaanderman, MD, PhD
study chair · Maastricht University Medical Center
Gerard Pasterkamp, PhD
study chair · UMC Utrecht
Hester HM den Ruijter, PhD
study chair · UMC Utrecht

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion